Compare · RMD vs TNDM
RMD vs TNDM
Side-by-side comparison of ResMed Inc. (RMD) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.02B, about 22.1x TNDM ($1.27B).
- Over the past year, RMD is down 23.1% and TNDM is down 8.7% - TNDM leads by 14.3 points.
- TNDM has been more active in the news (30 items in the past 4 weeks vs 6 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- ResMed Inc.
- Tandem Diabetes Care Inc.
- Price
- $193.21-1.43%
- $18.47-4.35%
- Market cap
- $28.02B
- $1.27B
- 1M return
- -6.57%
- +0.00%
- 1Y return
- -23.07%
- -8.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 6
- 30
- Recent ratings
- 25
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.
Latest TNDM
- Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
- EVP, Chief Strategy Officer Gasser Elizabeth Anne gifted 7,160 shares and received a gift of 7,160 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by PRESIDENT & CEO Sheridan John F
- SEC Form 4 filed by EVP, Chief Strategy Officer Gasser Elizabeth Anne
- SEC Form 4 filed by EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh
- SEC Form 4 filed by EVP & Chief Operating Officer Kyrillos Jean-Claude
- SEC Form 4 filed by EVP & Chief Legal Officer Hansen Shannon Marie
- SEC Form 4 filed by EVP & Chief Admin. Officer Morrison Susan
- SEC Form 4 filed by EVP & Chief Technology Officer Carpenter Rick
- Tandem Diabetes Care upgraded by Wells Fargo with a new price target